Key Highlights

  • Net sales rose to USD 142.4 million from USD 138.7 million, and Gross Profit was USD 97.1 million.
  • Net income was USD 6.9 million versus USD 4.0 million, and adjusted EBITDA rose to USD 28.4 million.
  • Net interest expense fell to USD 3.8 million from USD 6.2 million after discretionary term Loan prepayments.
  • Operating income was USD 9.7 million, down from USD 11.3 million, as selling and administrative costs grew faster than sales.

Quarter in Numbers

Bioventus Inc. (NASDAQ:BVS), a medical technology company focused on orthopedic and pain treatments, reported third-quarter 2026 net sales of USD 142.4 million, up from USD 138.7 million in the quarter ended September 27, 2025. Gross profit was USD 97.1 million versus USD 94.2 million, equal to a gross Margin of 68.2% by our calculation. Selling, general and administrative expense rose to USD 82.9 million from USD 78.7 million, and Research and Development expense rose 17.5% to USD 3.4 million from USD 2.9 million, mostly on salaries and consulting costs.

Operating income was USD 9.7 million versus USD 11.3 million. Net interest expense fell to USD 3.8 million from USD 6.2 million, and the prior-year quarter included a USD 0.3 million loss on extinguishment of debt. Pre-tax income rose to USD 6.2 million from USD 4.7 million, and there was an income tax benefit of USD 0.7 million. Net Income was USD 6.9 million versus USD 4.0 million, and net income attributable to the company was USD 6.0 million, or USD 0.08 per diluted Class A share, versus USD 3.2 million, or USD 0.05. Adjusted EBITDA was USD 28.4 million versus USD 26.6 million.

Nine Months and Debt Reduction

For the nine months, net sales were USD 427.7 million versus USD 410.2 million, and adjusted EBITDA was USD 87.5 million versus USD 79.6 million. Net income was USD 47.0 million versus USD 10.0 million, helped by an income tax benefit of USD 21.0 million versus an expense of USD 1.6 million a year earlier, so the nine-month gain reflects a tax item as well as operating improvement. Earnings per diluted share were USD 0.60 versus USD 0.12.

The company made discretionary prepayments of USD 22.0 million, USD 20.0 million and USD 15.0 million on its 2025 term loan in the first, second and third quarters, a total of USD 57.0 million. Net interest expense for the nine months fell to USD 12.2 million from USD 21.2 million. Cash and cash equivalents were USD 30.7 million at September 26, 2026.

Commercial Commentary

Management said that momentum in disposables growth and new account wins continues into the fourth quarter, paving the way for growth acceleration in 2027, and that international Revenue accelerated 16% in the third quarter on talent additions and focus on select markets. The company also discussed an update to its 2026 financial guidance on the earnings call.

The 10-Q notes that a large private insurance payer implemented changes to its claims data management and billing systems in the third quarter of 2025, which the company said could result in significantly higher rebate claims for its hyaluronic acid viscosupplement products.

Cost and Leverage Indicators

Selling and administrative costs grew 5.4% while net sales grew 2.7% by our calculation, which compressed operating income. Items to track include rebate dynamics with private payers, international growth, the pace of further debt prepayments and the relationship between selling expense and sales growth.